BIOGEN INC. - COMMON STOCK
230.57
17-May-24 14:59:59
15 minutes delayed
Stocks
+0.53
+0.23%
Today's range
226.43 - 230.83
ISIN
N/A
Source
NASDAQ
-
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
19 Oct 2023 06:30:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK
03 Oct 2023 09:31:01 By NetDania Notify
-
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
29 Sep 2023 15:06:00 By Nasdaq GlobeNewswire
-
Biogen Completes Acquisition of Reata Pharmaceuticals
26 Sep 2023 07:59:54 By Nasdaq GlobeNewswire
-
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
25 Sep 2023 00:02:57 By Nasdaq GlobeNewswire
-
Biogen Appoints Jane Grogan as Head of Research
06 Sep 2023 06:30:00 By Nasdaq GlobeNewswire
-
Biogen to Acquire Reata Pharmaceuticals
28 Jul 2023 06:05:44 By Nasdaq GlobeNewswire
-
19 Jul 2023 18:30:00 By Nasdaq GlobeNewswire
-
06 Jul 2023 19:00:00 By Nasdaq GlobeNewswire
-
30 Jun 2023 15:06:00 By Nasdaq GlobeNewswire
-
Biogen Announces Changes to Its Board of Directors
12 Jun 2023 16:14:01 By Nasdaq GlobeNewswire
-
NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK
12 Jun 2023 08:45:06 By NetDania Notify
-
09 Jun 2023 17:45:00 By Nasdaq GlobeNewswire
-
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
15 May 2023 18:30:00 By Nasdaq GlobeNewswire
-
25 Apr 2023 14:04:23 By Nasdaq GlobeNewswire
-
Biogen Appoints Adam Keeney as Head of Corporate Development
04 Apr 2023 06:30:00 By Nasdaq GlobeNewswire
-
30 Mar 2023 18:30:00 By Nasdaq GlobeNewswire
-
30 Mar 2023 18:30:00 By Nasdaq GlobeNewswire
-
29 Mar 2023 07:45:00 By Nasdaq GlobeNewswire